SOLENO THERAPEUTICS, INC.
SLNOLoading price...
Overview
Previous Close39.49
Open52.30
Ask66.96
Bid52.26
Day's Range52.15 - 52.38
52 Week Range29.43 - 90.32
PE Ratio(TTM)133.97
Market Cap2.81B
Volume58M
Avg. Volume1.69M
12 Months Earnings-175.85M
12 Months Revenue0.00
Profit/Loss
| PARTICULARS | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 184.43M | 184.43M | 38.67M | 25.11M | 32.26M |
| Profit after Tax (Net Income) | -175.85M | -175.85M | -38.99M | -24.07M | -30.91M |
Company Profile
Sector: Healthcare
Industry: Biotechnology
HQ Location: Redwood City, United States
Website: https://soleno.life
Chairman, President, CEO & COO: Dr. Anish Bhatnagar M.D.
Employees: 182
About Company:
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.